Author: Newsdesk

Posted on

American Public University System Renames its School of Business in Honor of President Emeritus Dr. Wallace E. Boston

Naming Pays Tribute to Dr. Boston Building APUS as a Trailblazer of Affordable Online Higher Education

PR Newswire

CHARLES TOWN, W.Va., Nov. 19, 2020 /PRNewswire/ — American Public University System (APUS) has renamed its business school the Dr. Wallace E. Boston School of Business, to commemorate Dr. Boston’s nearly two decades of leadership as a C-level executive and board member at APUS and its parent company, American Public Education, Inc. (Nasdaq: APEI). 

Dr. Boston led APUS as President and CEO during a period of accelerated growth – in both student enrollment and revenue. APUS has 86,300 active students (as of Sept. 30, 2020), roughly ten times the size of the student body at the start of his 15-year tenure. Dr. Boston, now president emeritus at APUS, previously served as APUS president up until his retirement in August 2020 and had also served as CEO of APEI through September 2019.  

“Dr. Boston has an unwavering commitment to student success and has not only built our university into a premier online higher education provider, he has helped define the future of online education,” said APUS Board of Trustees Chairman Alfred M. Gray, the 29th Commandant of the U.S. Marine Corps. “Our School of Business is building on this strong foundation, and it provides a relevant, accessible and inclusive learning environment for tomorrow’s aspiring business leaders.”

APUS’s School of Business has conferred more than 26,500 degrees and certificates. The School offers 51 online degree and certificate programs; 22 degrees are at the master’s and bachelor’s levels, including the Master of Business Administration (MBA) and Bachelor of Business Administration (BBA).

“I’m deeply honored by the tribute and am confident that the school will help students achieve rewarding careers for generations to come,” said Dr. Boston. “I have been fortunate to work with so many dedicated individuals to help better prepare hundreds of thousands of students for successful careers across private sector, public service and the military.”

Dr. Boston helped APUS and APEI achieve many milestones including a successful initial accreditation with the Higher Learning Commission of the North Central Association in 2006, the initial public offering on NASDAQ in 2007, and the acquisition of the Hondros College of Nursing (in 2013). His dedication to making higher education affordable and accessible has resulted in APUS being well positioned for the future.

The APUS School of Business’s mission is to prepare students to be principled leaders in the global business community by leveraging technology and best practices focused on the practical application of knowledge. The school’s courses are reviewed on an ongoing basis in consultation with industry leaders from Fortune 500 companies and beyond. APUS’s undergraduate and graduate business programs have specialty accreditation from the Accreditation Council for Business Schools and Programs (ACBSP), an affiliation achieved in 2011. The BA in Human Resources and the BA in Management, Human Resource Concentration have been approved by the Society for Human Resource Management (SHRM) for being in alignment with its educational standards.

The Business School offers numerous associate, bachelor’s, and master’s degree programs and certificate courses including business, management, transportation and logistics, entrepreneurship, analytics and supply chain management. All programs address core topics such as accounting, management, operations, human resources, international business, and economics, to prepare our graduates transitioning in the global world of work.

Supporting Resources

About American Public University System
American Public University System, recipient of the Online Learning Consortium’s (OLC) Gomory Award for Quality Online Education and five-time recipient of OLC’s Effective Practice Award, offers more than 200 online degree and certificate programs through American Public University and American Military University, the #1 provider of education to the U.S. military* and the top university nationwide for veterans using their GI Bill benefit** (based on student enrollment data). Over 101,400 alumni worldwide have benefited from APUS’s inclusive, relevant curriculum and flexible online delivery model. For more information, visit www.apus.edu.
*Based on FY 2019 DoD tuition assistance data, as reported by Military Times, 2020.
**Based on FY 2019 Department of Veterans Affairs (VA) data, as reported by Military Times, 2020.  

CONTACT

Frank Tutalo

Director of Public Relations
571-358-3042
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/american-public-university-system-renames-its-school-of-business-in-honor-of-president-emeritus-dr-wallace-e-boston-301177460.html

SOURCE American Public University System

Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Wells Fargo & Company (WFC)

Shareholders with $50,000 losses or more are encouraged to contact the firm

PR Newswire

LOS ANGELES, Nov. 19, 2020 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 29, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Wells Fargo & Company (“Wells Fargo” or the “Company”) (NYSE: WFC) common stock between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Wells Fargo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/wells-fargo-and-company/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On April 14, 2020, Wells Fargo announced its first quarter 2020 financial results in a press release. Therein, the Company announced a $4 billion provision expense to account for expected credit delinquencies, including $940 million in net charge-offs on loans and debt securities and a $3.1 billion reserve build.

On this news, the Company’s stock price fell $4.54, or 14%, over three consecutive trading sessions to close at $26.89 per share on April 16, 2020.

On May 5, 2020, Wells Fargo filed its quarterly report with the SEC for first quarter 2020, in which it stated that Wells Fargo’s collateralized loan obligations (“CLOs”) investments fell 9% and that the Company suffered $1.7 billion in unrealized losses on its CLO investments during the quarter.

On this news, the Company’s stock price fell $1.74, or 6%, over two consecutive trading sessions to close at $25.61 per share on May 6, 2020.

On June 10, 2020, Wells Fargo’s Chief Financial Officer, John Shrewsberry, presented at the Morgan Stanley Virtual US Financials Conference, during which he stated that the second quarter reserve build would be even “bigger than the first quarter” due to continued deterioration in the Company’s credit portfolio.

On this news, the Company’s stock price fell $5.84, or 18%, over two consecutive trading sessions to close at $26.79 per share on June 11, 2020.

On July 14, 2020, Wells Fargo announced its second quarter 2020 financial results in a press release, disclosing a $9.5 billion provision expense to account for expected credit delinquencies.

On this news, the Company’s stock price fell $1.16, or 5%, to close at $24.25 per share on July 14, 2020.

On October 14, 2020, Wells Fargo announced a $769 million provision expense for third quarter 2020, but the Company’s CFO stated that further deterioration of the credit portfolio had been forestalled due to short-term customer accommodations provided since the start of the pandemic.

On this news, the Company’s stock price fell $1.49, or 6%, to close at $23.25 per share on October 14, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loans were to customers of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, CLOs and CMBS on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, the Company’s statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading; and (8) as a result of the foregoing, the Company was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased Wells Fargo common stock during the Class Period, you may move the Court no later than December 29, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-wells-fargo–company-wfc-301177477.html

SOURCE Glancy Prongay & Murray LLP

Posted on

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN)

PR Newswire

BENSALEM, Pa., Nov. 19, 2020 /PRNewswire/ —  ­­Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”).  

Investors suffering losses on their Neovasc investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

In December 2018, the Company filed a Q-Sub submission to the U.S. Food and Drug Administration (“FDA”) that contained safety and efficacy results from Neovasc’s clinical studies, as well as supporting data from peer-reviewed journals.

On February 20, 2019, Neovasc announced that, despite “Breakthrough Device Designation,” the FDA review team recommended that the Company collect further pre-market blinded data prior to submitting a Pre-Market Approval (“PMA”) application.

On November 1, 2019, the Company announced that it would submit a PMA application for the Reducer without gathering further evidence, against the FDA’s recommendation. Neovasc claimed that “the clinical evidence already available will be sufficient to not further delay the availability of this Breakthrough medical device for the treatment of U.S. patients.”

On October 28, 2020, before the market opened, the Company announced that an FDA advisory panel voted overwhelmingly against the safety and effectiveness of the Reducer. The panel noted concerns with the Company’s clinical data, including “that the lack of blinding assessment made the primary endpoint difficult to interpret.” As a result, the panel reached a consensus “that additional premarket randomized clinical data was necessary.”

On this news, the Company’s share price fell $0.77, or 42%, to close at $1.06 per share on October 28, 2020, on unusually heavy trading volume.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Neovasc securities during the Class Period, you may move the Court no later than January 5, 2021to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:http://www.prnewswire.com/news-releases/deadline-reminder-law-offices-of-howard-g-smith-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-neovasc-inc-nvcn-301177455.html

SOURCE Law Offices of Howard G. Smith

Posted on

DEINOVE signs an Evaluation and Technology Development License with DSM

DEINOVE signs an Evaluation and Technology Development License with DSM

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment to tackle the global challenge of antimicrobial resistance and the need for next-generation active ingredients for Health, announces the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living.

Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.

“This collaboration with a major player in the field of animal nutrition is totally in line with our R&D partnering strategy in the non-therapeutic activities and underlines the quality of the work that has been done in the Color-2B program”
commented Alexis Rideau, Deputy CEO of DEINOVE.
“We hope that the evaluation and technology development program will lead to the launch of a new active ingredient that has been brought to light by DEINOVE from its proprietary strain collection.”

ABOUT DEINOVE

DEINOVE is a French biotech company pioneer in the exploration and exploitation of biodiversity from the natural environment to tackle the global challenge of antimicrobial resistance and the need for next-generation active ingredients for Health.

The Company has built a unique collection of over 10,000 bacterial strains and has developed a fully integrated technological platform that brings together the best of biological culture, synthetic biology and micro-biotechnology.

Today, DEINOVE has several development programs underway, including the antibiotic candidate   DNV3837, in a Phase II clinical trial in severe gastrointestinal infections with Clostridioides difficile, a real therapeutic challenge. Through its other program AGIR (Antibiotics against Resistant Infectious Germs), supported by Bpifrance, it is also continuing its exploration of biodiversity to supply its portfolio with new molecules. It relies on its own biodiversity and on the one entrusted to it by other specialists in the field.

DEINOVE has also developed and brought to market four particularly innovative active ingredients: two products produced by Deinococcus geothermalis (phytoene and neurosporene), as well as two cell extracts developed in collaboration.

DEINOVE, located in the Euromédecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally. It is listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056).

CONTACTS

Investors
Mario Alcaraz
Chief Financial and Administrative Officer
Phone: +33 (0)4 48 19 01 00
[email protected]

 

Media                                                                                                      
ALIZE RP – Caroline Carmagnol
Phone: +33 (0)6 64 18 99 59
[email protected]
 

 

Attachment



Posted on

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alibaba Group Holding Limited (BABA)

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alibaba Group Holding Limited (BABA)

BENSALEM, Pa.–(BUSINESS WIRE)–
Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) securities between October 21, 2020 and November 3, 2020 inclusive (the “Class Period”).

Investors suffering losses on their Alibaba investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

Alibaba is an online and mobile commerce company. Alibaba owns a 33% equity interest in Ant Small and Micro Financial Services Group Co., Ltd. (“Ant Group”), a financial technology company that is best known for operating Alipay, one of the largest mobile and online payments platforms.

On July 20, 2020, Ant Group announced that it had begun the process of a concurrent initial public offering (“IPO”) on the Shanghai and Hong Kong stock exchanges.

On October 26, 2020, Ant Group priced its IPO and was set to raise $34.5 billion, making it the largest public offering in history.

On November 2, 2020, Financial Times reported that Chinese regulators had met with Ant Group’s controller Jack Ma, executive chairman Eric Jing, and Chief Executive Officer Simon Hu. The article stated that, though regulators did not provide details, “the Chinese word used to describe the interview – yuetan – generally indicates a dressing down by authorities.” The article also included a statement from Ant Group that it will “implement the meeting opinions in depth.”

On November 3, 2020, the IPO was suspended because Ant Group “may not meet listing qualifications or disclosure requirements due to material matters” related to the meeting with regulators the previous day and “the recent changes in the Fintech regulatory environment.”

On this news, the Company’s share price fell $25.27, or 8%, to close at $285.57 per share on November 3, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Ant Group did not meet listing qualifications or disclosure requirements for certain material matters; (2) that certain impending changes in the Fintech regulatory environment would impact Ant Group’s business; (3) that, as a result of the foregoing, Ant Group’s IPO was reasonably likely to be suspended; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Alibaba securities during the Class Period, you may move the Court no later than January 12, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

[email protected]

www.howardsmithlaw.com

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Interface, Inc. (TILE)

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Interface, Inc. (TILE)

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Interface, Inc. (“Interface” or the “Company”) (NASDAQ: TILE) securities between March 2, 2018 and September 28, 2020 inclusive (the “Class Period”).

If you suffered a loss on your Interface investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/interface-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Interface is a modular flooring company that designs, produces, and sells modular carpet products primarily in the Americas, Europe, and the Asia-Pacific.

On April 24, 2019, Interface revealed that in November 2017, it had received a request for information and documents from the U.S. Securities and Exchange Commission (“SEC”) “in connection with an investigation into the Company’s historical quarterly earnings per share [“EPS”] calculations and rounding practices during the period 2014-2017.” The Company further disclosed that it had “received subpoenas from the SEC in February 2018, July 2018 and April 2019 requesting additional documents and information” and that Interface had conducted an internal investigation into these issues, at the SEC’s request.

On this news, Interface’s stock price fell $1.43 per share, or 8.37%, to close at $15.66 per share on April 25, 2019, thereby injuring investors.

On September 28, 2020, the SEC issued an enforcement order following its investigation into Interface’s historical quarterly EPS calculations and rounding practices. The Company agreed to pay a $5 million fine to resolve the matter and was ordered to cease and desist from violating the federal securities laws. The SEC also disclosed that “Interface employees caused Interface to produce documents in response to Commission investigative requests that were suggestive of contemporaneous support for journal entries that, in truth, did not exist at the time the entries were recorded,” and that they had altered certain documents after the SEC’s investigation initiated.

On this news, the Company’s stock price fell $0.20 per share, or 3.13%, over the following two trading sessions to close at $6.18 per share on September 29, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (2) consequently, Interface, inter alia, reported artificially inflated income and EPS in 2015 and 2016; (3) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Interface securities during the Class Period, you may move the Court no later than January 11, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

[email protected]

www.glancylaw.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN)

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioMarin Pharmaceuticals, Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”).

If you suffered a loss on your BioMarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at  https://www.glancylaw.com/cases/biomarin-pharmaceuticals-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

BioMarin is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s product candidates include, as well as others, valoctocogene roxaparvovec, an investigational adeno-associated virus (“AAV”) gene therapy, which is in Phase 3 clinical development for the treatment of patients with severe hemophilia A.  

On August 19, 2020, BioMarin announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s Biologics License Application (“BLA”) for valoctocogene roxaparvovec. Therein, the FDA concluded that the “differences between Study 270-201 (Phase 1/2) and the Phase 3 study limited its ability to rely on the Phase 1/2 study to support durability of effect.” As a result, the FDA recommended that BioMarin “complete the Phase 3 Study and submit two-year follow-up safety and efficacy data on all study participants.”

On this news, the Company’s stock price fell $41.82 per share, or 35%, to close at $76.72 per share on August 19, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the disparities between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the FDA would not approve the BLA for valoctocogene roxaparvovec without additional data; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.  

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired BioMarin securities during the Class Period, you may move the Court no later than November 24, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
www.glancylaw.com  
[email protected]



Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Peabody Energy Corporation (BTU)

Shareholders with $250,000 losses or more are encouraged to contact the firm

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 27, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Peabody Energy Corporation (“Peabody” or the “Company”) (NYSE: BTU) common stock between April 3, 2017 and October 28, 2019, inclusive (the “Class Period”).

If you suffered a loss on your Peabody investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/peabody-energy-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Peabody is the largest coal mining company in the world with 23 coal mines organized into six business segments. Its largest segment is the Australian Metallurgical Mining segment, which accounted for 23.1% of Peabody’s revenue in 2016. Peabody’s most profitable operation is the North Goonyella mine, which is within the Australian Metallurgical Mining segment, and in 2017, the mine generated 20% of the Company’s total operating profit.

On September 28, 2018, Peabody announced that it did “not expect any production from North Goonyella in the fourth quarter of 2018” due to a fire occurring within the mine.

On this news, the Company’s stock price fell $5.54, or over 13%, to close at $35.64 per share on September 28, 2018, thereby injuring investors.

Then, on February 6, 2019, Peabody reported disappointing financial results for fourth quarter 2018 due to remediation costs and lack of production at the North Goonyella mine. The Company also announced that production would not resume at the mine until the “early months of 2020.”

On this news, the Company’s stock price fell $3.80, or 11%, to close at $32.05 per share on February 6, 2019, thereby injuring investors further.

Then, on October 29, 2019, Peabody disclosed that operations at the North Goonyella mine would not resume for three or more years due to local regulators’ strict restrictions.

On this news, the Company’s stock price fell $3.56, or 22%, to close at $12.48 per share on October 29, 2019, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (2) the Company failed to follow its own safety procedures; and (3) as a result, the North Goonyella mine was at a heightened risk of shutdown; (4) the Company’s low-cost plan to restart operations at the North Goonyella mine posed unreasonable safety and environmental risks; (5) the Australian body responsible for ensuring acceptable health and safety standards, the Queensland Mines Inspectorate (“QMI”), would likely mandate a safer, cost-prohibitive approach; and (6) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production; and (7) that, as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Peabody common stock during the Class Period, you may move the Court no later than November 27, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
www.glancylaw.com  
[email protected]



Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pintec Technology Holdings Limited (PT)

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 30, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Pintec Technology Holdings Limited (“Pintec” or the “Company”) (NASDAQ: PT) securities pursuant and/or traceable to Pintec’s October 2018 initial public offering (“IPO” or the “Offering”).   

If you suffered a loss on your Pintec investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/pintec-technology-holdings-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

In October 2018, Pintec completed its IPO in which it sold more than 3.7 million American Depositary Shares (“ADSs” or “shares”) at $11.88 per share. 

On July 30, 2019, after the market closed, Pintec filed its fiscal 2018 annual report, in which it restated previously disclosed financial results. Among other things, Pintec reported net income of $315,000 for fiscal 2018, compared to its prior disclosure of $1.068 million net income. The Company also disclosed that there were material weaknesses in its internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs. 

On this news, Pintec’s share price fell $0.53, or more than 13%, over the next several trading sessions, to close at $3.40 per share on August 5, 2019, thereby injuring investors. 

On June 15, 2020, after the market closed, the Company disclosed that it could not timely file its fiscal 2019 annual report and that it anticipated reporting a significant change in results of operations. Specifically, Pintec disclosed that it “erroneously recorded revenue earned from certain technical service fee on a net basis” for fiscal 2017 and 2018. Moreover, the Company “announced a net loss of RMB906.5 million in the full year of 2019 due to RMB890.7 million of provision for credit loss in amounts due from a related party, Jimu Group, and RMB200 million of impairment in prepayment for long-term investment.” 

By the initiation of this action, Pintec shares were trading as low as $0.92 per share, a nearly 92% decline from the $11.88 per share IPO price. 

The complaint alleges that the Registration Statement was false and misleading and omitted to state material facts. Specifically, Defendants failed to disclose to investors: (1) that Pintec erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) that there were material weaknesses in the Company’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) that, as a result of the foregoing, Pintec’s financial results for fiscal 2017 and 2018 had been misstated; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Pintec’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. 

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Pintec securities, you may move the Court no later than November 30, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com



Posted on

DEADLINE ALERT for EOLS, LVS, IPHA, JPM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Nov. 19, 2020 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected].

Evolus, Inc. (NASDAQ: EOLS) 
Class Period: February 1, 2019 – July 6, 2020
Lead Plaintiff Deadline: December 15, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the real source of botulinum toxin bacterial strain, along with the manufacturing processes used to develop Jeuveau, originated with and were misappropriated from Medytox; (2) sufficient evidentiary support existed for the allegations that the Company misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau; (3) as a result, the Company faced a real threat of regulatory and/or court action, barring the import, marketing, and sale of Jeuveau; (4) which in turn seriously threatened Evolus’ ability to commercialize Jeuveau in the United States and generate revenue; and (5) that any revenues generated from the sale of Jeuveau were based on Evolus’ unlawful actions, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox; and (6) that, as a result, the Company’s public statements were materially false and misleading at all relevant times.

Las Vegas Sands Corp. (NYSE: LVS)
Class Period: February 27, 2016 – September 15, 2020
Lead Plaintiff Deadline: December 21, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that weaknesses existed in Marina Bay Sands’ casino control measures pertaining to fund transfers; (2) that the Marina Bay Sands’ casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company’s anti-money laundering procedures; (3) that the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (4) that Las Vegas Sands had inadequate disclosure controls and procedures; (5) that, consequently, all the foregoing issues were untimely disclosed; and (6) that, as a result, the Company’s public statements were materially false and misleading at all relevant times.

Innate Pharma SA
. (NASDAQ: IPHA)
Class Period: March 10, 2020 – September 8, 2020
Lead Plaintiff Deadline: December 22, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

JPMorgan Chase & Co
. (NYSE: JPM)
Class Period: February 23, 2016 – September 23, 2020
Lead Plaintiff Deadline: December 23, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) traders at the Company, with the knowledge and consent of their superiors, manipulated the precious metals market by “spoofing,” or placing fake orders to generate the appearance of market demand; (2) the Company had insufficient controls and compliance protocols to enable it to identify and stop the misconduct; (3) the Company’s earnings in the physical commodity market were, at least in part, ill-gotten; (4) such conduct would result in enhanced regulatory scrutiny; (5) the Company provided misleading information to CFTC investigators at early stages of the investigation into the misconduct; (6) resolution of the governmental investigation into the Company would result in a record-breaking $920 million fine; and (7) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com